ChemicalBook > CAS DataBase List > Ambrisentan

Ambrisentan

Ambrisentan Structure
Ambrisentan
  • CAS No.177036-94-1
  • Chemical Name:Ambrisentan
  • CBNumber:CB71011125
  • Molecular Formula:C22H22N2O4
  • Formula Weight:378.42
  • MOL File:177036-94-1.mol
Ambrisentan Property
  • Melting point >150°C (dec.)
  • Boiling point 551.1±60.0 °C(Predicted)
  • Density 1.228±0.06 g/cm3(Predicted)
  • storage temp. Sealed in dry,2-8°C
  • solubility DMSO (Slightly), Methanol (Slightly)
  • form Solid
  • pka 0.97±0.10(Predicted)
  • color White to Off-White
  • optical activity [α]/D +160 to +190°, c =0.5 in methanol
  • Merck 14,384
  • InChI InChI=1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)
  • InChIKey OUJTZYPIHDYQMC-UHFFFAOYSA-N
  • SMILES C(OC1N=C(C)C=C(C)N=1)(C(O)=O)C(OC)(C1=CC=CC=C1)C1=CC=CC=C1
  • FDA UNII HW6NV07QEC
  • ATC code C02KX02
  • UNSPSC Code 41121706
  • NACRES NA.77
Safety
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal wordDanger
  • Hazard statements H360FD
  • Precautionary statements P201-P308+P313
Ambrisentan Price More Price(4)
  • Brand: Sigma-Aldrich(India)
  • Product number: SML2104
  • Product name : Ambrisentan
  • Purity: ≥98% (HPLC)
  • Packaging: 10MG
  • Price: ₹13730.7
  • Updated: 2022/06/14
  • Buy: Buy
  • Brand: Sigma-Aldrich(India)
  • Product number: SML2104
  • Product name : Ambrisentan
  • Purity: ≥98% (HPLC)
  • Packaging: 50MG
  • Price: ₹55222.5
  • Updated: 2022/06/14
  • Buy: Buy
  • Brand: TCI Chemicals (India)
  • Product number: A2966
  • Product name : Ambrisentan
  • Purity: 
  • Packaging: 20MG
  • Price: ₹3500
  • Updated: 2022/05/26
  • Buy: Buy
  • Brand: TCI Chemicals (India)
  • Product number: A2966
  • Product name : Ambrisentan
  • Purity: 
  • Packaging: 100MG
  • Price: ₹7900
  • Updated: 2022/05/26
  • Buy: Buy

Ambrisentan Chemical Properties,Usage,Production

  • Description Ambrisentan is a selective endothelin-A (ETA) receptor antagonist introduced for the oral treatment of patients with pulmonary arterial hypertension (PAH), to improve exercise capacity and delay clinical worsening. It is the third ET-receptor antagonist to be marketed for this indication behind bosentan and sitaxsentan. PAH is a rare disease of the small pulmonary arteries characterized by vascular proliferation and remodeling, resulting in a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, and ultimately, right ventricular failure and premature death. Early symptoms of PAH include gradual onset of shortness of breath, fatigue, palpitation, edema, and fainting. Endothelin-1 (ET-1), a potent vasoconstrictor and smooth muscle mitogen, is a key contributor to the acceleration of the disease, and its effects are mediated through activation ofETA and ETB receptors.
  • Description Ambrisentan is a nonpeptide endothelin A (ETA) receptor antagonist (IC50s = 0.251, 0.316, 0.398, 251, and 630 nM for rat preparations of heart, bladder, kidney, lung, and cerebral cortex, respectively). It inhibits contraction of isolated rabbit aortic rings induced by endothelin-1 (ET-1; ) by 43.23% when used at a concentration of 1 μM. Ambrisentan inhibits ET-1-induced contraction of human pulmonary and radial arteries in vitro (Kd = 0.042 and 0.11 μM, respectively). In a rat model of neonatal hyperoxic lung injury, ambrisentan (20 mg/kg per day, s.c.) reduces pulmonary arterial hypertension (PAH) as well as decreases PAH-induced right ventricular hypertrophy (RVH) and peak RV pressure. Formulations containing ambrisentan have been used to treat PAH.
  • Chemical Properties White to Off White Solid
  • Originator Abbott (US)
  • Uses antihypertensive;endothelin receptor antagonist
  • Uses Nonpeptide endothelin ETA receptor antagonist. Antihypertensive
  • Definition ChEBI: Ambrisentan is a diarylmethane.
  • brand name Letairis
  • General Description Ambrisentan, (+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid(Letairis), is a potent ETA selective endothelin antagonist that,is indicated, in the treatment of pulmonary arterial hypertension(PAH). PAH is a rare disease that if left untreated has ahigh mortality rate. In June of 2007, the FDA granted approvalof ambrisentan for once-daily treatment of PAH.Studies have shown that it improves a 6-minute walk by about30 to 60 m for patients receiving placebo.
  • Clinical Use Endothelin A (ETA) receptor antagonist:
    Treatment of pulmonary arterial hypertension
  • Synthesis Both the discovery and process routes to the synthesis of ambrisentan have been published and the process route is described as shown in the scheme. Reacting a mixture of benzophenone (14) and sodium methoxide in THF at 0??C with methylchloroacetate over a four hour period provided glycidate 15 which was taken forward without purification to the subsequent step. Addition of ptoluenesulfonic acid monohydrate to a solution of glycidate 15 in methanol was followed by heating at reflux and distilling out the solvent until the temperature reached 66??C. While the solution was still refluxing, 10% potassium hydroxide was added and the remaining organic solvent was distilled out until the temperature reached 94??C, providing complete hydrolysis to acid 16. The reaction was cooled to room temperature and diluted with water and methyl tert-butylether (MTBE) then acidified with 10% sulfuric acid. The MTBE layer was separated and taken to the next step. Additional MTBE and methanol were added to the crude acid 17 and the resulting mixture was heated at reflux. (S)-1-(4-chlorophenyl) ethylamine was added to the refluxing solution and the resulting mixture was allowed to cool to 0-5??C slowly at a rate of 10??C/h which resulted in crystallization of the salt 19 in 33% overall yield from benzophenone and 99% e.e. The chiral hydroxyl acid salt 19 was mixed with sulfone 20 and lithium amide in a toluene/DMF mixture and heated at 45??C for 12 hours to give, after acidic workup and crystallization, ambrisentan (II) in 84% yield as a colorless powder with 99.8% e.e.

    Synthesis_177036-94-1

  • Drug interactions Potentially hazardous interactions with other drugs
    Ciclosporin: concentration of ambrisentan doubled with an increased risk of side effects; maximum dose 5 mg daily.
  • Metabolism Ambrisentan is glucuronidated via several UGT isoenzymes (UGT1A9S, UGT2B7S and UGT1A3S) to form ambrisentan glucuronide (13%). Ambrisentan also undergoes oxidative metabolism mainly by CYP3A4 and to a lesser extent by CYP3A5 and CYP2C19 to form 4-hydroxymethyl ambrisentan (which has little activity) which is further glucuronidated to 4-hydroxymethyl ambrisentan glucuronide.
    Ambrisentan is excreted mainly by the liver, although the contribution of hepatic metabolism and biliary excretion is unknown.
  • storage Store at +4°C
  • References [1] vatter h, seifert v. ambrisentan, a non-peptide endothelin receptor antagonist. cardiovascular drug reviews, 2006, 24(1): 63-76.
    [2] barst r j. a review of pulmonary arterial hypertension: role of ambrisentan. vascular health and risk management, 2007, 3(1): 11.
Ambrisentan Preparation Products And Raw materials
Raw materials
Preparation Products
Ambrisentan Suppliers
Global(385)Suppliers
  • Supplier：
    Capot Chemical Co.,Ltd.
  • Tel：+86-（0）57185586718<br/>+86-13336195806
  • Email：sales@capot.com
  • Country：China
  • ProdList：29730
  • Advantage：60
  • Supplier：
    Henan Tianfu Chemical Co.,Ltd.
  • Tel：+86-0371-55170693<br/>+86-19937530512
  • Email：info@tianfuchem.com
  • Country：China
  • ProdList：21628
  • Advantage：55
  • Supplier：
    career henan chemical co
  • Tel：+86-0371-86658258<br/>+8613203830695
  • Email：sales@coreychem.com
  • Country：China
  • ProdList：29858
  • Advantage：58
Ambrisentan Spectrum
177036-94-1, AmbrisentanRelated Search:
  • Other APIs
  • Pharmaceuticals
  • Intermediates & Fine Chemicals
  • Heterocycles
  • Aromatics
  • APIs
  • 高纯试剂
  • 杂质对照品
  • 抑制剂
  • 配体家族
  • 药靶配体
  • 杂质
  • 化学试剂
  • 精细化工原料
  • 生物化工
  • 抗肺动脉高压药
  • 化工
  • 药物杂质及中间体
  • 科研试剂
  • 医用原料
  • 医药原料
  • 原料药
  • 医药中间体
  • 杂环类
  • 小分子抑制剂
  • 医药原料药
  • 安倍生坦,10 MM DMSO 溶液
  • 安贝生坦标准品
  • (R,S)-安布里生坦
  • (2S)-2-(4,6-二甲基嘧啶-2-基)氧基-3-甲氧基-3,3-二苯基丙酸
  • 安贝(倍)生坦
  • 安立生坦API
  • 安倍生坦AMBRISENTAN(研发中)
  • 苯丙酸, Α-[(4,6-二甲基-2-嘧啶基)氧基]-Β-甲氧基-Β-苯基-, (ΑS)-
  • 安立生坦
  • 安倍生坦
  • 2-(4,6-二甲基嘧啶-2-基)氧基-3-甲氧基-3,3-二苯基丙酸
  • 安贝生坦
  • 安利生坦
  • 安立生坦杂质
  • 安倍生坦(标准品)
  • (S)-2 - ((4,6-二甲基嘧啶-2-基)氧基)-3-甲氧基-3,3-二苯基丙酸
  • 安立生坦及中间体和杂质
  • 安立生坦 (安倍生坦)
  • 177036-94-1
  • Ambrisentan - Bio-X ?
  • Ambrisentan, 10 mM in DMSO
  • Anlisentan
  • Benzenepropanoic acid, α-[(4,6-dimethyl-2-pyrimidinyl)oxy]-β-methoxy-β-phenyl-, (αS)-
  • (R,S)-Ambrisentan
  • Ambrisentan AKSci B500
  • Ambrisentan 98% 177036-94-1
  • (2S)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoicaci
  • Ambelsentan intermediate
  • AmbrisentanQ: What is Ambrisentan Q: What is the CAS Number of Ambrisentan Q: What is the storage condition of Ambrisentan Q: What are the applications of Ambrisentan
  • ((S)-Ambrisentan)
  • Ambrisentan USP/EP/BP
  • (S)-2-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropionic Acid

Home

My